High-Throughput Screening for Positive Allosteric Modulators Identified Potential Therapeutics against Acetylcholinesterase Inhibition. (October 2015)

• Record Type: Journal Article
• Authors: Chapleau, Richard R.; McElroy, Craig A.; Ruark, Christopher D.; Fleming, Emily J.; Ghering, Amy B.; Schlager, John J.; Poeppelman, Lee D.; Gearhart, Jeffery M.
• Is Part Of: Journal of biomolecular screening. Volume 20:Number 9(2015)
• Page Start: 1142
• Page End: 1149
• Publication Date: 2015-10
• Subjects: acetylcholinesterase -- medical countermeasure -- nerve agent pretreatment -- organophosphate poisoning -- positive allosteric modulator; Drugs -- Analysis -- Periodicals; Drugs -- Testing -- Periodicals; Biomolecules -- Analysis -- Periodicals; 572.36
• DOI: 10.1177/1087057115591006
• Languages: English
• ISSNs: 1087-0571

Abstract

The current standard of care for treatment of organophosphate (OP) poisoning includes pretreatment with the weak reversible acetylcholinesterase (AChE) inhibitor pyridostigmine bromide. Because this drug is an AChE inhibitor, similar side effects exist as with OP poisoning. In an attempt to provide a therapeutic capable of mitigating AChE inhibition without such side effects, high-throughput screening was performed to identify a compound capable of increasing the catalytic activity of AChE. Herein, two such novel positive allosteric modulators (PAMs) of AChE are presented. These PAMs increase AChE activity threefold, but they fail to upshift the apparent IC50 of a variety of OPs. Further development and optimization of these compounds may lead to pre- and/or postexposure therapeutics with broad-spectrum efficacy against pesticide and nerve agent poisoning. In addition, they could be used to complement the current therapeutic standard of care to increase the activity of uninhibited AChE, potentially increasing the efficacy of current therapeutics in addition to altering the therapeutic window.